Navigation Links
Essilor's 2008 First-Quarter Report
Date:4/22/2008

CHARENTON-LE-PONT, France, April 23 /PRNewswire-FirstCall/ -- Essilor International, the world leader in ophthalmic optics, today announced consolidated revenue of EUR762.2 million for the three months ended March 31, 2008, representing a reported 3.6% increase on the first quarter of 2007.

Like-for-like growth amounted to 6.2%, in line with the Company's announced annual growth target. Changes in scope of consolidation accounted for 4% of growth for the period, corresponding mainly (3.3%) to acquisitions made in 2007, with the rest contributed by businesses acquired since January 1. The 6.6% negative currency effect primarily reflected the 13.9% fall in the dollar against the euro and, to a lesser extent, the 12.6% decline in the British pound.
Consolidated revenue for the first three months of 2008

EUR millions First-quarter First-quarter % change Like-for-like

2008 change(1)

2007 as

reported

Consolidated revenue 762.2 735.6 + 3.6% + 6.2%

Europe 346.4 334.5 + 3.6% + 3.7%

North America 318.3 311.7 + 2.1% + 8.2%

Asia-Pacific 69.2 65.3 + 5.9% + 6.6%

Latin America 28.3 24.1 + 17.6% + 14.0%

(1)Based on a comparable scope of consolidation and at constant exchange rates.

In Europe, growth was impacted by the unfavorable comparison with first-quarter 2007, when revenue rose 8.6% like-for-like. In addition, there were substantially fewer selling days than in the year-earlier period. Germany and the Eastern European countries reported a strong performance.

In the United States, where demand generally remained strong, growth was led by the successful launch of the sixth generation of Transitions(R) variable-tint lenses and of the Crizal Avance(TM) with Scotchguard(TM) Protector lenses.

Subsidiaries in the Asia-Pacific region reported strong growth, except in Australia where economic conditions are difficult. Business in Japan was in line with past performance, while operations in China, the ASEAN countries and India continue to enjoy robust growth and a steady improvement in the product mix.

Lastly, operations in Brazil, Argentina and Mexico all had a very good quarter.

Highlights of the quarter

Since the beginning of 2008, Essilor has announced ten acquisitions in North America, Europe and Asia, which are expected to contribute an aggregate EUR64 million in full-year revenue.

Prescription laboratories acquired in North America included Interstate Optical, Advance Optical Sales, Empire Optical of California and Future Optics in the United States; Rainbow Optical Labs in Porto Rico and WestLab Optical in Canada.

In Europe, Essilor acquired Galileo, a leading Italian marketer of prescription and stock lenses; Optymal, the Company's distributor in Bulgaria; and O'Max, a Dutch distributor of optometry and lens edging instruments.

In India, Essilor purchased Rx 20/20, a prescription laboratory.

In addition, Nikon-Essilor has announced the purchase of a minority stake in Encore Optics, a Connecticut-based prescription laboratory in the United States.

Share buybacks

In the first quarter, Essilor purchased 1,700,000 Company shares on the open market for a total of EUR65 million. These buybacks were part of the policy implemented since 2003 to offset the dilution resulting from the conversion of OCEANE bonds, the exercise of stock options and the granting of performance shares.

Cash position - Debt

Due to the normal seasonal fluctuations in business, as well as acquisitions, share buybacks and capital expenditure, Essilor's net cash and cash equivalents decreased by almost EUR135 million during the first quarter.

Following the conversion of 83,614 OCEANE bonds during the period, there are currently 3,375,448 bonds outstanding, representing 55.9% of the original issue.

A conference call in French will be held today at 9:00 a.m., Paris time.

The number to dial is: +33(0)-1-70-99-34-68

The conference will be available for later listening at:

http://hosting.3sens.com/Essilor/20080423-1726AB95/fr/

A conference call in English will follow at 10:00 a.m., Paris

time.

The number to dial is: +44(0)208-817-9301

The conference will be available for later listening at:

http://hosting.3sens.com/Essilor/20080423-1726AB95/en/

------------------------

Investor calendar

Wednesday, May 14, 2008: Annual Shareholders' Meeting

Thursday, July 17, 2008: First-half revenue announced

------------------------

Essilor International is the world leader in ophthalmic optical products, offering a wide range of lenses under the flagship Varilux(R), Crizal(R), Essilor(R) and Definity(R) brands to correct myopia, hyperopia, presbyopia and astigmatism. Essilor operates worldwide through 15 production sites, 270 lens finishing laboratories and local distribution networks. The Essilor share trades on the Euronext Paris market and is included in the CAC 40 index. (ISIN: FR 0000121667; Reuters: ESSI.PA; Bloomberg: EF:FP).

Investor Relations and Financial Communications

Veronique Gillet - Sebastien Leroy

Phone: +33(0)1-49-77-42-16

http://www.essilor.com


'/>"/>
SOURCE Essilor
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. First-Quarter 2008 Results Teleconference/Webcast for VNUS Medical Technologies Interrupted Due to Technical Difficulties
2. Triple-S Management Corporation Schedules First-Quarter Earnings Release and Webcast
3. Cynosure to Announce First-Quarter 2008 Financial Results on April 29
4. VNUS Medical Technologies to Report First-Quarter 2008 Results and Webcast Teleconference on April 21
5. Hospira Hosts Conference Call for First-Quarter 2008 Earnings
6. Abbott Hosts Conference Call for First-Quarter Earnings
7. Cardinal Health To Announce First-Quarter Results on November 5
8. NuVasive Reports First Quarter 2008 Financial Results
9. CuraGen Reports First Quarter 2008 Financial Results
10. American Cancer Society report details cancer prevention efforts
11. Albemarle Reports Record Quarterly Net Sales and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... Trusted debt-reduction firm CreditAssociates, LLC has announced two ... in excess of $835 million in resolved debt for its clients. , Credit card ... of the categories of debt settled by the company. With more than a decade ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... Canyon Ranch to its recently formed Corporate Roundtable, a group of ... system and a sustainable world. , Canyon Ranch is a unique collection of ...
(Date:9/19/2017)... RESTON, VA (PRWEB) , ... ... ... future of medication management to the present, Mirixa Corporation recently unveiled the ... has continually redefined and reinvented how medication management services are delivered. Based ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... Driving Dynamics ... Safety Training Company by Training Industry Inc. as part of its mission to continually ... , Selection to the first annual 2017 Top 20 Health and Safety Training Companies ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... neurosurgeon, has received a big bump in sales after recently going live ... available on the Wal-Mart Stores-owned Jet.com, StackedNutrtion.com, RonnieColemanNutrition.com, RevNutrition.com and Go4ItNutrition.com. ...
Breaking Medicine News(10 mins):
(Date:8/29/2017)... 2017 ivWatch, LLC, the leading provider of continuous monitoring ... has been awarded an Innovative Technology contract from Vizient, Inc., the ... ... in the early detection of peripheral IV infiltration and extravasation events ... The Innovative Technology contract was awarded to ...
(Date:8/28/2017)... division of LightScalpel ®, LLC, is announcing its new line of ... American veterinary laser surgery innovation, Aesculight® is revolutionizing veterinary laser surgery once ... ... VetScalpel laser. Dr. Duclos practices veterinary dermatology at the Animal Skin and ... ...
(Date:8/24/2017)... -- BioBridges, a Career Portfolio® Management company providing integrated ... announce its corporate sponsorship of the upcoming fourth annual ... event will benefit charitable foundations affiliated with each band. ... to return once again as a sponsor of the ... Jason Falchuk , BioBridges Founding Partner. "Our life sciences ...
Breaking Medicine Technology: